Emerging Therapies Underscore Need for Genomic Testing in HR+/HER2– Breast Cancer

Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormome receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.

Related Keywords

Medical College Of Wisconsin ,Wisconsin ,United States ,Kari Wisinski ,Yee Chung Cheng ,Marina Sharifi ,Lubna Chaudhary ,Mark Burkard ,Division Of Hematology ,Department Of Medicine ,Uw Wisconsin Carbone Cancer Center ,College Of Wisconsin ,University Of Wisconsin Uw Carbone Cancer Center ,Uw Carbone Cancer Center ,Breast Cancer Disease Oriented Team ,Carbone Cancer Center ,Science Summit ,Endowed Professor ,Medical Oncology ,Palliative Care ,Carbone Cancer ,Cancer Center ,Chung Cheng ,Medical College ,Patients With Metastatic Hormone Receptor Positive ,Her2 Negative Breast Cancer ,D ,The University Of Wisconsin Carbone Cancer Center ,Malinda West ,The Medical College Of Wisconsin ,Us ,Phd ,